Objective To compare the characteristics and outcomes of neonates with mild hypoxic-
ischemic encephalopathy (HIE) who received hypothermia versus standard care. Study …

Objective To re-visit short-term outcomes and associated risk factors of newborns with
hypoxic-ischemic encephalopathy (HIE) in an era where hypothermia treatment (HT) is …

Objective Hypoxic–ischemic encephalopathy (HIE) is a leading cause of morbidity and
mortality in neonates. Therapeutic hypothermia (TH) has improved outcomes and mortality …

Objective To evaluate variations in management of therapeutic hypothermia (TH) for
neonatal hypoxic-ischemic encephalopathy (HIE) among international clinical sites and to …

Despite advances in obstetric care, hypoxic ischemic encephalopathy (HIE) remains a
significant disease burden. We determined the national trends of HIE prevalence …

Background The incidence of hypoxic-ischemic encephalopathy (HIE) is 0.5 per 1,000 live
births. Current standard treatment is therapeutic hypothermia (cooling) begun within 6 hours …

Introduction: Accurately diagnosing and treating infants with mild forms of hypoxic ischemic
encephalopathy (HIE) is important, as the majority of neonates with signs and symptoms of …

Objective Therapeutic hypothermia (TH) commenced soon after birth for neonatal hypoxic
ischaemic encephalopathy (HIE) improves survival and reduces neurodisability. Availability …

Background Therapeutic hypothermia is standard of care for babies with moderate/severe
hypoxic-ischaemic encephalopathy and is increasingly used for mild encephalopathy …

Neonatal encephalopathy affects 2 to 5 of every 1000 live births and represents a major
cause of mortality and long-term morbidity in affected infants. Hypoxic ischemic …